Clinuvel Pharmaceuticals Ltd

CUV

Company Profile

  • Business description

    Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.

  • Contact

    535 Bourke Street
    Level 22
    MelbourneVIC3000
    AUS

    T: +61 396604900

    https://www.clinuvel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    16

Stocks News & Analysis

stocks

Undervalued ASX listed biotech refocuses

Fair value uneffected by suspended early-stage clinical trials.
funds

10 reasons many fund managers are now blank spaces

It looks easy from the outside, but asset management is a tough game. Winners can win big, but there are far more strugglers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,660.3022.500.26%
CAC 407,773.935.79-0.07%
DAX 4024,051.20117.970.49%
Dow JONES (US)42,215.73117.030.28%
FTSE 1008,745.9329.480.34%
HKSE23,289.77283.61-1.20%
NASDAQ19,175.8774.930.39%
Nikkei 22537,965.10467.88-1.22%
NZX 50 Index12,418.89137.581.12%
S&P 5005,912.1723.620.40%
S&P/ASX 2008,434.7024.900.30%
SSE Composite Index3,347.4915.96-0.47%

Market Movers